Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases

被引:113
作者
Freites Nunez, Dalifer D. [1 ,2 ]
Leon, Leticia [1 ,2 ,3 ]
Mucientes, Arkaitz [1 ,2 ]
Rodriguez-Rodriguez, Luis [1 ,2 ]
Font Urgelles, Judit [4 ]
Madrid Garcia, Alfredo [1 ,2 ]
Colomer, Jose, I [1 ,2 ]
Jover, Juan A. [4 ,5 ]
Fernandez-Gutierrez, Benjamin [4 ]
Abasolo, Lydia [1 ,2 ]
机构
[1] Fdn Invest Biomed Hosp Clin San Carlos, Rheumatol Dept, Madrid, Spain
[2] Fdn Invest Biomed Hosp Clin San Carlos, IDISSC, Madrid, Spain
[3] Univ Camilo Jose Cela, Dept Hlth & Educ, Madrid, Spain
[4] Hosp Clin San Carlos, Rheumatol Dept, Madrid, Spain
[5] Univ Complutense Madrid, Med Dept, Madrid, Comunidad De Ma, Spain
关键词
CORONAVIRUS;
D O I
10.1136/annrheumdis-2020-217984
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives To describe patients with autoimmune inflammatory rheumatic diseases (AIRD) who had COVID-19 disease; to compare patients who required hospital admission with those who did not and assess risk factors for hospital admission related to COVID-19. Methods An observational longitudinal study was conducted during the pandemic peak of severe acute respiratory syndrome coronavirus 2 (1 March 2020 to 24 April). All patients attended at the rheumatology outpatient clinic of a tertiary hospital in Madrid, Spain with a medical diagnosis of AIRD and with symptomatic COVID-19 were included. The main outcome was hospital admission related to COVID-19. The covariates were sociodemographic, clinical and treatments. We ran a multivariable logistic regression model to assess risk factors for the hospital admission. Results The study population included 123 patients with AIRD and COVID-19. Of these, 54 patients required hospital admission related to COVID-19. The mean age on admission was 69.7 (15.7) years, and the median time from onset of symptoms to hospital admission was 5 (3-10) days. The median length of stay was 9 (6-14) days. A total of 12 patients died (22%) during admission. Compared with outpatients, the factors independently associated with hospital admission were older age (OR: 1.08; p=0.00) and autoimmune systemic condition (vs chronic inflammatory arthritis) (OR: 3.55; p=0.01). No statistically significant findings for exposure to disease-modifying antirheumatic drugs were found in the final model. Conclusion Our results suggest that age and having a systemic autoimmune condition increased the risk of hospital admission, whereas disease-modifying antirheumatic drugs were not associated with hospital admission.
引用
收藏
页码:1393 / 1399
页数:7
相关论文
共 21 条
  • [1] [Anonymous], COVID 19 SITUACION C
  • [2] Covid-19 in Critically Ill Patients in the Seattle Region - Case Series
    Bhatraju, Pavan K.
    Ghassemieh, Bijan J.
    Nichols, Michelle
    Kim, Richard
    Jerome, Keith R.
    Nalla, Arun K.
    Greninger, Alexander L.
    Pipavath, Sudhakar
    Wurfel, Mark M.
    Evans, Laura
    Kritek, Patricia A.
    West, T. Eoin
    Luks, Andrew
    Gerbino, Anthony
    Dale, Chris R.
    Goldman, Jason D.
    O'Mahony, Shane
    Mikacenic, Carmen
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (21) : 2012 - 2022
  • [3] Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
    Chen, Nanshan
    Zhou, Min
    Dong, Xuan
    Qu, Jieming
    Gong, Fengyun
    Han, Yang
    Qiu, Yang
    Wang, Jingli
    Liu, Ying
    Wei, Yuan
    Xia, Jia'an
    Yu, Ting
    Zhang, Xinxin
    Zhang, Li
    [J]. LANCET, 2020, 395 (10223) : 507 - 513
  • [4] Facing the SARS-CoV-2 (COVID-19) outbreak with IL-6R antagonists
    Corominas, Hector
    Castellvi, Ivan
    Domingo, Pere
    Casademont, Jordi
    [J]. EUROPEAN JOURNAL OF RHEUMATOLOGY, 2020, 7 : S107 - S109
  • [5] The Rheumatologist's Role in COVID-19
    Cron, Randy Q.
    Chatham, W. Winn
    [J]. JOURNAL OF RHEUMATOLOGY, 2020, 47 (05) : 639 - 642
  • [6] The Giants (biologicals) against the Pigmies (small molecules), pros and cons of two different approaches to the disease modifying treatment in rheumatoid arthritis
    Favalli, Ennio Giulio
    Matucci-Cerinic, Marco
    Szekanecz, Zoltan
    [J]. AUTOIMMUNITY REVIEWS, 2020, 19 (01)
  • [7] COVID-19 with Pulmonary Involvement. An Autoimmune Disease of Known Cause
    Fernandez-Gutierrez, Benjamin
    [J]. REUMATOLOGIA CLINICA, 2020, 16 (04): : 253 - 254
  • [8] Are my patients with rheumatic diseases at higher risk of COVID-19?
    Figueroa-Parra, Gabriel
    Mayela Aguirre-Garcia, Gloria
    Magdalena Gamboa-Alonso, Carmen
    Camacho-Ortiz, Adrian
    Angel Galarza-Delgado, Dionicio
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (06) : 839 - +
  • [9] Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry
    Gianfrancesco, Milena
    Hyrich, Kimme L.
    Al-Adely, Sarah
    Carmona, Loreto
    Danila, Maria, I
    Gossec, Laure
    Izadi, Zara
    Jacobsohn, Lindsay
    Katz, Patricia
    Lawson-Tovey, Saskia
    Mateus, Elsa F.
    Rush, Stephanie
    Schmajuk, Gabriela
    Simard, Julia
    Strangfeld, Anja
    Trupin, Laura
    Wysham, Katherine D.
    Bhana, Suleman
    Costello, Wendy
    Grainger, Rebecca
    Hausmann, Jonathan S.
    Liew, Jean W.
    Sirotich, Emily
    Sufka, Paul
    Wallace, Zachary S.
    Yazdany, Jinoos
    Machado, Pedro M.
    Robinson, Philip C.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (07) : 859 - 866
  • [10] Guan WJ, 2020, EUR RESPIR J, V55, DOI [10.1183/13993003.00547-2020, 10.1371/journal.pone.0240308, 10.1183/13993003.00597-2020]